NEW YORK (GenomeWeb News) — Upstream Biosciences has hired Genpathway to use its chromatin immunoprecipitation assays in its cancer biomarker-validation studies, Upstream Bio said today.
 
Genpathway will use its assays to “help elucidate critical parameters involving specific gene transcription factors and pathways” and provide “critical information for the next phase of Upstream's program to validate its first two cancer biomarkers and drug response assay,” according to Upstream.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.